More Science AIDS: Genetic Clues from HIV Elite Controllers Could Lead to Better Vaccines, Cancer Treatments A rare group of HIV-positive individuals need no medicine to keep the virus in check. Their good fortune could point the way to more powerful treatments--and perhaps a vaccine By Bruce D. Walker THIS IS A PREVIEW. Buy this digital issue or subscribe to access the full article. Already a subscriber or purchased this issue? Sign In Richard Renaldi One day in early 1995 a man named bob massie walked into my office at the outpatient clinic of Massachusetts General Hospital in Boston. Massie told me he had been infected with HIV—the virus that causes AIDS—for 16 years and yet had never shown any symptoms. My physical examination confirmed he was healthy, in stark contrast to all other patients I saw that day. At that time, a new combination of drugs was being tested that would eventually slow the progressive decline in immune function that HIV caused. In 1995, however, most people who had been infected with HIV for a decade or more had already progressed to AIDS—the stage marked by the inability to fight off other pathogens. The young man standing before me had never taken anti-HIV medication and strongly believed that if I learned the secret to his good fortune, the information could help others to survive what was then generally thought to be a uniformly fatal disease. Massie was born with hemophilia, a blood-clotting disorder. In those days, nearly all hemophiliacs were HIV-positive because they were infused repeatedly with blood products agglomerated from thousands of donors—none of whom were screened for HIV until the mid- to late 1980s. (Today hemophiliacs receive artificial clotting factors, which pose no risk of HIV contamination.) Some of Massie's blood samples that had been stored for a study revealed that he had contracted HIV in 1978. Yet every test I conducted on him or his stored samples showed that the amount of virus in his blood was vanishingly small and that his immune responses seemed as strong as ever. THIS IS A PREVIEW. Buy this digital issue or subscribe to access the full article. Already a subscriber or purchased this issue? Sign In Buy Digital Issue $5.99 Add To Cart Digital Issue + Subscription $39.99 Subscribe ADVERTISEMENT Scientific American is a trademark of Scientific American, Inc., used with permission © 2015 Scientific American, a Division of Nature America, Inc. All Rights Reserved.